GEN Exclusives

More »

Feature Articles

More »
Oct 15, 2011 (Vol. 31, No. 18)

Two Technologies Are Better Than One

Tool Combinations Lay Waste to Obstacles in Small Molecule Discovery and Development

  • Caliper Life Sciences recently hosted a meeting where scientists described use of the company’s technologies to support high-quality drug candidate discovery and optimization. The application of Caliper’s imaging technology, automation/liquid-handling robotics, and chip-based microfluidics technologies to meet and overcome technical challenges in both drug discovery and in developing in vitro and in vivo assays were among the topics discussed.

  • Networking

    Michelle Palmer, Ph.D., director of discovery and preclinical research, chemical biology platform, Broad Institute of Harvard and MIT, described the institute’s approach to integrating novel technologies for identifying small molecules that drive translation research and therapeutics.

    The chemical biology and novel therapeutics platforms were established at the Broad to discover small molecules that impact biology and medicine and to innovate the process through which probes and drugs are both discovered and developed.

    The Broad enterprise, she explained, “is part of a large network, the MLSMR, funded by NIH. Through that network, we collaborate on 25 new projects a year. Projects start with assay development, then progress to hit selection, and prioritization. The hits are then put through a battery of secondary assays to determine which are the most promising for chemical optimization. We work in close collaboration with our chemistry team. We then provide the data and the chemical tool back to the research community through NIH’s probe report.”

    Dr. Palmer said that the Broad applies standard HTS assays as well as novel technologies to prioritize hits coming out of screens and then to discover and understand the mechanism of action of a particular compound. “This knowledge informs the medicinal chemistry process and ability to detect, quantify, and understand the effects of the compound in various cell and animal models.”

    The Broad applies a variety of integrated technologies to achieve this level of detail. These include next-generation chemistry (diversity-oriented synthesis), small molecule microarrays (SMMs), microfluidic-based chromatin modifying enzyme assays, multiplexed gene-expression measurements, and SILAC proteomics for target ID.

    Dr. Palmer believes that automation has had a big impact on the small molecule characterization process, because, “the more you can do to automate a process and improve data consistency, quality, and reproducibility, the easier it is to think about the data. The data-visualization tools that are evolving to allow us to look at large quantities and types of data permit a much more unbiased approach to identifying the mechanism.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »